ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

New Sample Preparation System Improves Proteomics Research Productivity

Thermo Scientific AccelerOme Automated Sample Preparation Platform brings greater reproducibility and standardization to LC-MS workflows

ASMS 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, is helping proteomics researchers increase productivity and free up time for more value-added activities when generating high quality samples for analysis, using a new automated sample preparation system that integrates within any LC-MS workflow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005315/en/

Thermo Scientific AccelerOme Automated Sample Preparation Platform (Photo: Business Wire)

Thermo Scientific AccelerOme Automated Sample Preparation Platform (Photo: Business Wire)

The Thermo Scientific AccelerOme Automated Sample Preparation Platform eliminates the need for labor-intensive, manual sample preparation for LC-MS analysis, including the associated method development and reagent sourcing. This allows users to focus on higher value tasks. Automated sample preparation also overcomes the challenge of maintaining reproducibility with manual methodologies, and the new platform’s pre-built validated methods and kit format reagents reduce further any risk of user error. The resulting peptide samples are of consistent high-quality. A novel built-in UV measurement of final peptide concentration prior to LC-MS analysis allows the standardization of sample peptide input for LC-MS analysis, another metric that adds to the quality, reliability and robustness of the final experimental result. The platform supports the use of peptide standards to monitor LC-MS system performance, enabling instrument health monitoring during acquisition or through post-acquisition data analysis.

Thermo Fisher Scientific is showcasing the AccelerOme Automated Sample Preparation Platform during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022 in Booth 400 at the Minneapolis Convention Center, Minneapolis, Minnesota and at the Hilton Minneapolis Grand Ballrooms E, F, G.

“Proteomics researchers in academia and biopharma face an array of challenges, especially demands for speed and productivity,” said Andreas Huhmer, senior marketing director, omics research, life sciences mass spectrometry, Thermo Fisher Scientific. “Appropriate automated sample preparation systems for LC-MS have a crucial role. They provide support for core facilities, where flexibility and reproducibility are essential. In research labs, sample preparation systems are necessary to help to automate complex samples and large sample sets in order to rapidly generate rigorous data for publication, and in biopharma, these systems offer speed and productivity in commercialization. The AccelerOme platform provides a solution for proteomics LC-MS workflows.”

The AccelerOme sample preparation platform, designed with a unique experimental design tool, combines reliable and reproducible hardware with easy-to-use software and commercially available reagent kits for both label-free and TMT multiplexing applications. A software wizard guides users through each step, facilitating proteomics research to newcomers to the field. The new platform is optimized to fit into the Thermo Scientific Orbitrap MS ecosystem. End-to-end software, sample and study factor information are transferred from sample input all the way through to LC-MS acquisition through data analysis with Thermo Scientific Proteome Discoverer Software.

For more information on the Thermo Fisher solutions exhibited at ASMS 2022, please visit www.thermofisher.com/ASMS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.00
+2.08 (1.00%)
AAPL  264.18
-8.77 (-3.21%)
AMD  200.21
-3.47 (-1.70%)
BAC  49.83
-2.47 (-4.72%)
GOOG  311.43
+4.28 (1.39%)
META  648.18
-8.83 (-1.34%)
MSFT  392.74
-8.98 (-2.24%)
NVDA  177.10
-7.79 (-4.21%)
ORCL  145.40
-4.91 (-3.27%)
TSLA  402.51
-6.07 (-1.49%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.